Of note, subgroup analysis also exhibited the significant association of p16 hypermethylation and poor DFS of patients with NSCLC in studies with REMARK score greater than 12 (HR 2.12, 95% CI: 1.21–3.72) (Figure 2B). This evidence concerns the gene CDKN2A and non-small cell lung carcinoma.